52240-11-6

Upstream product

• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 52240-12-7 6-(4-acetylamino-phenyl)-5-methyl-2H-pyridazin-3-one 
• 36725-27-6 SKF 93741 
• 95355-13-8 6-(4-Acetylaminophenyl)-5-hydroxymethyl-2,3,4,5-tetrahydro-pyridazin-3-one 

Downstream Products

• 131741-08-7 (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-propanedinitrile 
• 131741-36-1 (4-(4-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)carbohydrazonoyl dicyanide 
• 360795-13-7 6-(4-hydrazinophenyl)-5-methyl-2H-pyridazin-3-one 

Relevant academic research and scientific papers

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

Disclosed are compounds, such as pyridazinones, that can be, inter alia, used for treating cancer.

(-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]pr

Optically substantially pure (-) enantiomer of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono)propanedinitrile or pharmaceutically acceptable salt thereof, intermediates and a process for the preparation are described. The product is useful as a cardiotonic agent, antihypertensive and vasodilator for the treatment of congestive heart failure.